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Abstract
Plasmacytoid dendritic cells (pDCs) are the major producers of type I IFN in response to viral infection and have been shown
to direct both innate and adaptive immune responses in vitro. However, in vivo evidence for their role in viral infection is
lacking. We evaluated the contribution of pDCs to acute and chronic virus infection using the feeble mouse model of pDC
functional deficiency. We have previously demonstrated that feeble mice have a defect in TLR ligand sensing. Although
pDCs were found to influence early cytokine secretion, they were not required for control of viremia in the acute phase of
the infection. However, T cell priming was deficient in the absence of functional pDCs and the virus-specific immune
response was hampered. Ultimately, infection persisted in feeble mice. We conclude that pDCs are likely required for
efficient T cell priming and subsequent viral clearance. Our data suggest that reduced pDC functionality may lead to chronic
infection.
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Introduction
Plasmacytoid dendritic cells (pDCs) are a rare subset of DCs first
appreciated in the blood and peripheral lymphoid tissues of
humans and notable for producing extremely high amounts of
type I interferon [1]. Thereafter, three studies reported the
identification and characterization of the murine counterpart [2–
4] which was paired with an increased interest and ability to
understand pDC function in vivo. pDCs generate ,10006more
type I interferon than any other cell type which accounts for the
majority of circulating type I interferon during acute viral
infections (reviewed in [5]). Therefore, it has been postulated that
pDCs play a crucial role in disease and particularly viral infections
[5]. Despite this tremendous biochemical capacity, a potent
physiological role for pDCs in vivo has remained more difficult to
identify. Part of this problem can be attributed to the lack of
suitable tools to study pDC function in vivo. Several models have
been recently created to address this issue including E2-2 deficient
mice [6], BDCA-2-DTR [7] and Siglec-H-DTR [8] transgenic
mice. In addition to the numerous activating functions demon-
strated previously, some models have also demonstrated that pDCs
can exert significant inhibitory function by controlling the
homeostasis of regulatory CD4+ T cells [8]. Therefore, despite
the classic immune stimulating functions first intimated for pDCs
given their potent production of type I interferon, the ultimate role
of pDCs in specific infections remains unclear.
Using a novel genetic screen we reported the utility of a mutant
allele of Slc15a4 (solute carrier family 15, member 4) named
‘‘feeble’’ to study pDC function in vivo. This ENU-induced single
base pair transition resulted in pDCs unable to sense TLR ligands
due to a defect in the SLC15A4 histidine transporter [9].
Importantly, TLR responses are specifically ablated in pDCs
from feeble mice (a defect seen in the traditional Slc15a4 knockout
as well [10]), but intact in other cell types. Also, pDC number is
maintained in mutants. Thus feeble mice provide a unique
condition where pDCs are present but largely deficient for their
function as producers of inflammatory cytokines [9]. This is in
contrast to previous murine models involving deletion of pDCs,
resulting in compensatory mechanisms within other immune
effectors that may obscure the intrinsic role of pDCs [8].
To address these questions of pDC function in vivo, we used the
natural mouse pathogen lymphocytic choriomeningitis virus
(LCMV) in an acute and chronic infection model. feeble mutants
displayed clearance kinetics similar to wild type mice after an acute
LCMV Armstrong infection. In contrast, LCMV Clone 13 (Cl13)
could not be contained by virus-specific T cells, thereby suggesting
a role for pDCs in controlling persistent viral infections.
Results/Discussion
PDCs are dispensable for early virus control but critical
for long-term clearance
In order to understand the functional role of pDCs in vivo, we
challenged feeble mice with murine pathogens. We observed a
striking deficit in the ability to control a persistent LCMV Cl13
infection without any significant change in the course of an acute
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infection from the parent LCMV Armstrong strain as measured by
viremia over time (Figure 1A). To ensure whether this defect was
specific to persistent (as opposed to acute infection), we harvested
organs from LCMV Armstrong infected mice at several time
points. LCMV Armstrong showed mild differences in infectious
titer 5 days post infection (dpi) which were not present at 10 dpi
(Figure S1) or anytime thereafter (for which we were unable to
detect infectious virus), consistent with our serum titer data.
As pDCs are known to respond rapidly to an infectious
challenge [5,7], we reasoned that this defect in immunity may be
due to a difference in Cl13 establishment during the initial phase
of the infection. To address this possibility, we harvested organs
from WT and feeble mice 5 and 8 days after Cl13 infection.
However, we found no difference in viral titer or tropism at this
stage of the infection (Figure 1BC). By 2 months post infection,
and consistent with our serum titer data (Figure 1A), we observed
that most organs known to harbor a persistent LCMV infection
sustained very high levels of virus in feeble in contrast to WT mice
(Figure 1D).
PDC dysfunction results in reduced T cell priming
Cognate T cell responses are critical in controlling persistent
viral infections. This is well documented for LCMV Cl13 infection
[11] but also for other, clinically relevant persistent infections such
as HIV, HBV and HCV [12]. Therefore, we evaluated T cell
function 8 days post LCMV Cl13 infection during the peak
response. In comparison to WT infection, feeble displayed
hypofunctional CD4+ and CD8+ T cell responses against
immunodominant LCMV epitopes (Figure 2AB). Consistent with
our findings in Figure 1, this defect was specific to a persistent
infection and not observed during LCMV Armstrong infection
(Figure S2.)
CD8+ T cell responses are instructed via both direct and cross-
presentation. LCMV Cl13 like many other persistent pathogens
directly inhibits APC function during infection [13]. In order to
avoid viral immune evasion strategies, cross-presentation may be
used by the host [14]. Thus, we reasoned that the feeble mutation
may attenuate cross-priming. To address this we used a sterile
model of inflammation depending on cross-presentation and type I
IFN signaling [15]. Seven days after immunization, we observed a
hypofunctional CD8+ T cell response in feeble as compared to WT
animals, indicating a defect in priming (Figure 2C). As the
magnitude of this defect was proportionally less than during
Cl13virus infection (Figure 2C vs. Figure 2AB), we hypothesized
that both pathways of antigen presentation require fully functional
pDCs. Consistent with this idea, we observed that mice mutant in
IRF7 (IRF7inept/inept), which is required for the type I interferon
response in pDCs, was similarly hypofunctional after sterile
immunization (Figure 2C).
Reduced T cell priming in feeble mice is due to a T cell
extrinsic dysfunction
Previously, we reported that the feeble mutation acted in pDCs
[9]. However, it was formally possible that this mutation in the
histidine transporter SLC15A4 could compromise T cell function
intrinsically. To test this hypothesis, we generated mixed bone
marrow chimeras in which the irradiated recipient was reconsti-
tuted with an equal portion of WT and feeble bone marrow
progenitor cells. In this setting we could determine whether there
was a competitive advantage between WT and mutant cells. We
did not detect a difference in the expansion nor functional activity
of CD4+ and CD8+ T cells 8 days post LCMV Cl13 infection
between WT and feeble cells (Figure 3AB). Similarly, when mixed
bone marrow chimeras were challenged with an antigen that must
be cross-presented, we did not observe any differences between
WT and feeble (Figure 3C). Therefore, the defect in antigen specific
feeble T cell responses was extrinsic to the T cells themselves.
To further address the location where the feeble mutation was
acting, we made use of OT-I TCR transgenic mice bearing CD8+
T cells specific for the model antigen ovalbumin [16]. We
generated OT-I; feeble double mutant mice and cultured naı¨ve
splenocytes ex vivo for 3 days in the presence of a greater than
1000-fold range of the cognate immunodominant epitope
SIINFEKL. We chose to assess proliferation as it is known to be
extremely sensitive to inhibition in CD8+ T cells [11]. We also
focused our efforts on CD8+ T cells given their established
importance in controlling persistent LCMV Cl13 infection [11] in
contrast to other cell types (e.g. B cells, NK cells [17,18]). No
differences were observed between OT-I and OT-I; feeble double
mutant mice with regards to proliferation (Figure S3). We
concluded that the feeble mutation was not required for T cell
function in this assay.
In addition, we considered whether the feeble mutation may
affect other cell types intrinsically and therefore have a contrib-
uting role towards the observed in vivo phenotype (Figure 1, 2).
Similarly to prior studies in which cDC function was intact in feeble
mice [9], we did not observe a defect in NK cell cytotoxicity
(Figure S4) or TLR responses of B cells and thioglycolate-elicited
macrophages (personal observations).
Given the intact intrinsic lymphocyte function observed
(Figures 3, S2, S3), we sought to evaluate other mechanisms
which could compromise the adaptive T cell response in vivo.
Diminished early inflammatory cytokine production in
feeble mice following virus infection
pDC are best recognized for their abundant production of type
I interferon and other cytokines [5]. Therefore we reasoned that a
defect in these secreted molecules may contribute to virus
susceptibility and a defect in antigen specific T cell activation
(e.g. as shown via pDC derived type I interferon [19–23]). To
address this possibility, we assessed cytokine/chemokine produc-
tion 1 and 8 days post infection in the circulation as a potential
Author Summary
The immune system consists of two arms aimed at fighting
infection. Innate immunity represents the first barrier of
defense to swiftly react – within minutes – following
intrusion by a pathogen. Adaptive immunity is activated a
few days later. Cross-talk between these two systems is
critical but the means of communication are not yet fully
understood. Plasmacytoid dendritic cells (pDCs) are innate
immune cells best recognized for their ability to produce
type I interferon (e.g. in response to viral infection.)
Evidence for pDCs to modulate the adaptive system in vivo
is only recent and still elusive. Using a newly described
mouse model named feeble that is characterized by
functional deficiency of pDCs, we analysed the role of
feeble in the context of acute and chronic viral infection.
We found that the feeble mutation affecting pDCs is
dispensable for immunity during an acute infection.
However our data show that feeble mice failed to control
a chronic infection. This was likely due to a reduction in
early cytokine secretion and improper activation of
adaptive T cells, resulting in virus persistence. Therefore
we propose that pDCs are critical for the resolution of
chronic infection by linking both arms of immunity.
Slc15a4 Is Required to Control a Persistent Virus
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contributing mechanism for our findings. We observed a reduction
in several cytokines with an almost complete loss in the serum
concentration of IFNc and MCP-1 (Figure 4). These two factors
are well known for their ability to both recruit and activate
professional antigen presenting cells (pAPCs) and may be
expressed by pDC in addition to other cell types. Therefore, we
reasoned that a defect may lie in the recruitment and/or activation
of pAPCs which could explain the in vivo specific defect in T cell
activation in feeble. Splenocytes were harvested at 0, 1, 3 and 5 days
post infection to quantitate both the numbers and activation of key
immune effector cells early during LCMV Cl13 infection (Figure
S5). We observed a mild difference in both the recruitment and
activation of pAPCs as measured by the total number of viable
cells and their functional markers MHC class I & class II in
addition to the costimulatory molecules CD80 and CD86 on the
three predominant pAPC (B cells, macrophages and dendritic
cells) early during infection (Figure S5BC). Defects in both the
total number and mean fluorescent intensity of functional markers
were most pronounced 1 dpi although some deficits were observed
3 dpi. However, these differences were largely not statistically
significant. Given the differences observed in cytokine/chemokine
serum levels observed acutely post infection (Figure 4) in
combination with a mild defect in the recruitment and activation
of pAPC to the spleen, we hypothesize that these defects
contribute in part to a more subtle and/or complex mechanism
present early on in feeble resulting in attenuation of T cell
responses, and that may involve other immune effectors.
Additionally, our findings may underlie an underappreciated
mechanism for pDC action.
Prophylactic activation of pDCs prevents viral persistence
Given the dramatic requirement we observed for pDCs in
controlling a persistent viral infection, we postulated that
manipulation of their function may be of therapeutic benefit. To
test this hypothesis, we used the TLR9 agonist type A cytosine
guanine oligodeoxynucleotide (CpG-ODN). WT mice were given
either vehicle or 2 ug CpG2216-ODN (a CpG motif specific for
pDC [24]) in dinucleotide-1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP) 4 hours before and after LCMV Cl13 infection
as well as 3 days post infection. We observed a window in which
CpG-ODN was effective in preventing viremia when administered
immediately prior to infection (Figure 5). Our findings demon-
strate the limitations and a potential starting point for using pDC
specific TLR agonists as an approach in the treatment of persistent
viral infections. This may be due to the already chronic
stimulation of pDCs under these conditions [5].
Nevertheless, our data also suggest a role for pDCs for the
priming of sterile adaptive immunity, which may be translated into
Figure 1. Slc15a4 is required to control chronic viral infection. Serum and organs were collected at the indicated times post LCMV infection
and infectious virus was titered. WT and feeble mice were infected i.v. with 26106 pfu of the acute LCMV Armstrong (Arm) strain or the persistent
LCMV Clone 13 (Cl13) strain (A). Serum was then harvested at the indicated time points for .4 months to enumerate viremia. After Cl13 infection,
organs were harvested from WT and feeble mice 5 dpi (B), 8 dpi (C), and 2 mpi (D), homogenized and titered for infectious virus. Individual replicates
and means are shown. Feeble, Slc15a4feeble/feeble mice; l.o.d., limit of detection. Representative data of 2 independent experiments are shown; n.=5
per group. Unless marked, p.0.05 between WT and feeble and not statistically significantly different.
doi:10.1371/journal.ppat.1002915.g001
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cancer therapy. Along this line, a recent study has shown that
pDCs may be the key effectors in eliminating malignant
melanoma with the clinically approved and prevalently used
TLR7 agonist imiquimod [25].
Very recently, a manuscript has been published, showing that
constitutive ablation of pDCs leads to virus persistence in mice
[26]. While these results complement our data, they also illustrate
differences. Contrary to pedigrees genetically lacking pDCs, feeble
mutants have normal pDC numbers and are on a pure C57BL/6J
background. Infection with 105 pfu of LCMV Docile resulted in
increased virus titers as early as 5 days post infection in pDC
lacking mice [26], while we observed prominently higher viremia
in feeble mutants only 2 months after challenge with 26106 pfu
LCMV Clone 13 (Figure 1D), and not during the early stage of the
infection. Together with the reduction in priming of feeble CD8+ T
cell upon sterile immunization (Figure 2C) our data demonstrate
that the impaired T cell function in absence of functional pDCs is
not secondary to failure in early virus control, as it may occur for
viral strains with high replication kinetics [27]. We also show that
the feeble mutation negatively impacts on the production of several
pro-inflammatory cytokines (Figure 4), yet without severely
affecting the recruitment and activation of pAPCs (Figure S5).
Furthermore, another group used the transgenic BDCA2-DTR
mouse [7] to deplete pDC during the revision of this manuscript
[28]. Interestingly, this study using LCMV Clone13 did not see a
difference in viremia upon depletion of pDC with diphtheria toxin.
As this model of pDC depletion results in ,90% loss of pDCs, we
suspect that this discrepancy in findings may be due to residual
function of the remaining pDC in the BDCA2-DTR mouse
model.
Regarding the timing of effects in our model, we note that
significant defects in CD4+ and CD8+ T cell function are
observed 8 days post infection. At this time, the amount of
infectious virus in several organs and the blood stream of feeble
mice are very similar to WT animals. However, subsequent to this
timepoint (8 dpi) we observe higher systemic viral loads in feeble
versus WT mice. As pDC activity is seen early by ourselves
(Figure 5) and others (reviewed in [5]) one may expect even higher
viral loads during the first week of infection in feeble mice, which we
do not observe. This may reflect a physiological ‘‘ceiling’’ of
Figure 2. Slc15a4 is required for antigen specific T cell responses in vivo. 8 days after LCMV Cl13 infection, splenocytes from WT and feeble
mice were cultured ex vivo with the indicated peptides at 1027 M, 1028 M (‘‘lo’’ concentration) or without peptide for 5 hours and then stained with
antibodies to quantitate T cell antigen specific production of IFN-c (A) and TNF-a (B). In (C) mice were primed with TAP12/2 5E1 fibroblasts
expressing the model antigen from Adeno E1B. Seven days after i.p. injection splenocytes from WT, feeble, and inept mice were cultured ex vivo with
the immunodominant antigen for 5 hours. Then IFN-c expression was quantitated in CD8+ T cells by flow cytometry. Mean and standard error of the
mean are shown. feeble, Slc15a4feeble/feeble mice; inept, IRF7inept/inept mice. Representative data of 2 independent experiments are shown. n$4 per
group of mice. Unless marked, p.0.05 between WT and feeble and not statistically significantly different.
doi:10.1371/journal.ppat.1002915.g002
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maximum viral load allowed by the mouse at this time. For
instance, when analyzing mice deficient in type I, type II or both
interferon receptors as compared to WT mice [29], splenic viral
loads were very similar between all four strains of mice during the
first week of infection. Differences between these strains were only
noticed subsequent to this time despite our knowledge of the
seminal role of interferons in the control of viral infection.
Likewise, in our studies we observe very early defects in cytokine
production (1 dpi) and early (8 dpi) defects in T cell function.
However, the differences in viral loads are not observed until after
8 dpi. CD4+ and CD8+ T cells are required for control of
persistent LCMV infection and adoptive transfer of these cells is
sufficient to eliminate a persistent LCMV infection [30,31].
Therefore, we suspect that like interferon receptor deficient
animals a maximum level of viremia is established during the
first 8 days of infection which is ultimately cleared by the
combined effort of CD4+ and CD8+ T cells in WT mice. However,
feeble mice lack effective CD4+ and CD8+ T cell responses
Figure 3. Defect in antigen specific feeble T cell responses is extrinsic. Equal numbers of bone marrow progenitors were harvested from WT
and feeble mice and transferred into feeble recipients to generate mixed bone marrow chimeras. .8 weeks post irradiation, mixed bone marrow
chimeras were challenged with LCMV Cl13. Eight days post infection splenocytes were harvested, counted, cultured with the indicated peptides for
5 hours, stained with antibodies, and analyzed by flow cytometry IFN-c production in CD8+ (A) and CD4+ (B) antigen specific T cells. In (C) mice were
primed with TAP12/2 5E1 fibroblasts expressing the model antigen from Adeno E1B. Seven days after i.p. injection splenocytes from mixed bone
marrow chimeras (prepared as above) were cultured ex vivo with the immunodominant antigen for 5 hours. Then IFN-c expression was quantitated in
CD8+ T cells by flow cytometry. Mean and standard error of the mean are shown. Feeble, Slc15a4feeble/feeble mice. n = 5 per group of mice. 1 of 2 similar
experiments is shown. Unless marked, p.0.05 between WT and feeble and not statistically significantly different.
doi:10.1371/journal.ppat.1002915.g003
Slc15a4 Is Required to Control a Persistent Virus
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Figure 4. Slc15a4 is required for specific acute inflammatory cytokine production. One and 8 days post LCMV Cl13 infection serum was
collected and the cytokines displayed were quantitated from WT and feeble mice. Individual replicates, mean and standard error of the mean are
shown. Representative data of 2 independent experiments are shown; n = 5 per group of infected mice. Unless marked, p.0.05 between WT and
feeble and not statistically significantly different.
doi:10.1371/journal.ppat.1002915.g004
Figure 5. Prophylactic treatment with CpG-DOTAP prevents persistent viral infection.WT mice were treated with vehicle or i.v. 2 mg CpG-
ODN in DOTAP (‘‘Rx’’) either 4 h prior, 4 h post or 3 days post infection with LCMV Cl13. Serum was collected at the indicated times post infection and
titered for infectious virus. CpG-DOTAP: CpG-A plus DOTAP (Roche); l.o.d., limit of detection. Mean and standard error of the mean are shown for 5
mice per group of infected mice. 1 of 2 similar experiments is shown. Unless marked, p.0.05 between treatment groups and not statistically
significantly different.
doi:10.1371/journal.ppat.1002915.g005
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(although the total # of splenocytes at this time is unchanged, data
not shown) and are unable to clear systemic infection during our
studies. We suspect that the defect in T cell function accounts for
the inability of feeble mice to control persistent viral infection.
Interestingly, the gene mutated in feeble mice, slc15a4, has been
implicated in NOD1 signaling in vivo [10]. Therefore, it is possible
that incomplete NOD1 signaling may contribute to defects in
controlling persistent viral infection in the presence of mutant
slc15a4. However, we believe this to be less likely than a role for
pDC function given the body of literature supporting NOD1 (a
receptor for peptidoglycan derivatives) function in bacterial
infections [32] versus the role of pDC in viral infections [5].
PDCs have also been implicated in the control of persistent
infections in humans. This is largely due to their potential function
for type I interferon production which directly augments T cell
function [19–23] and the observation that persistent infectious
viruses (e.g. HIV, HBV, HCV) actively suppress pDC function
[5,33,34]. Moreover, it is known that patients with higher HIV
viral loads and lower CD4+ T cell counts have a deficit in pDC
numbers which are not recovered with highly active anti-retroviral
therapy (HAART) (reviewed in [5]). Therefore, our work gives a
functional framework to better understand these observations. An
important extension of this work will be to address whether a
subset of HIV, HBV or HCV patients who are more susceptible to
disease progression have a functional compromise in pDC
function encoded genetically or otherwise that can be modulated
therapeutically. Our studies may provide a foundation to address
these and other clinically relevant questions pertaining to pDCs
and human disease.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocols were approved by the Institutional Animal Care and Use
Committee of The Scripps Research Institute (Protocol#:09-0098)
as well as the Institutional Animal Care and Use Committee of
Case Western Reserve University (Protocol#:2011-0200).
Mice
C57BL/6J mice were bred locally or ordered from Jackson
Laboratories. Slc15a4feeble/feeble (MGI: 4835997) and Irf7inept/inept
(MGI: 4442855) mutants have been described previously [9]. OT-
I mice have been described previously [16]. Compound mutants
were generated by intercrossing F1 progeny.
Viruses, focus-forming unit (FFU) assay
The Armstrong strain and Clone 13 variant of LCMV was
injected intravenously at a dose of 26106 PFU per mouse. Viral
titers were determined from serial dilutions of serum and organ
homogenate by a focus-forming assay on VeroE6 cells as described
previously [35].
Antibodies, intracellular cytokine staining and ex vivo
restimulation of T cells
The following antibodies were used for flow cytometry, to stain
splenocytes: CD3e (145-2C11, eBioscience), CD4 (L3T4,
eBioscience), CD8a (53-6.7, eBioscience), CD19 (MB19-1,
eBioscience), F4/80 (BM8, Biolegend), Mac-1 (M1/70, Biole-
gend), CD80 (B7-1, Biolegend), CD86 (GL1, Biolegend), MHC
Class I (28-14-8, Biolegend), MHC Class II (M5/114.15.2,
Biolegend), IFNc (XMG1.2, Biolegend), TNFa (MP6-XT22,
Biolegend). Cell populations were defined as follows: T cell
populations, CD3e+ and either CD4+ or CD8+; B cells, CD19+,
CD32,CD11c2; macrophages, F4/80hi, Mac-1hi; dendritic cells
CD11chi. Specific T-cell responses were determined ex vivo by
intracellular IFNc and TNFa staining after a 5 hour stimulation
with 1027 M peptide in the presence of brefeldin A (BD
Biosciences) as described before [35] unless otherwise indicated.
Antigen challenge with 5E1 cells
Tap12/2 5E1 mouse embryonic fibroblast cells were used to
access for a feeble dependent role in cross presentation. 107 5E1
cells were given i.p. per mouse. These cells express the Adeno E1B
192-200 immunodominant Db-restricted peptide [15]. Cells were
irradiated with 3000 rad prior to injection. Seven days after
injection, splenocytes were harvested and cultured ex vivo with
1027 M VNIRNCCYI for 5 hours. Then CD8+ T cell intracel-
lular cytokine production was quantitated by flow cytometry.
Serum cytokine detection
Blood samples were taken from the retro-orbital plexus of mice.
Cytokines (IFNc, MCP-1, TNFa, IL-6, IL-12p70 and IL-10) were
enumerated with the BD Mouse Inflammatory Cytometric Bead
Array per manufacturer’s instructions. IFNa was enumerated by
VeriKine Mouse Interferon-Alpha ELISA Kit per manufacturer’s
instructions.
Ovalbumin induced expansion of CD8+ T cells in OT-1
OT-1 transgenic mice [16] were bred onto the feeble allele to
produce double mutants. Splenocytes were harvested from OT-1;
feeble and OT-1 mice and incubated ex vivo for 3 days with the
immunodominant CD8+ ovalbumin epitope SIINFEKL under a
range of concentrations. CD8+ transgenic T cell proliferation was
quantitated with carboxyfluorescein succinimidyl ester (CFSE)
staining detected by flow cytometry and analyzed with FlowJo
software.
Mixed bone marrow chimera production
For bone marrow transplantation, bone marrow cells were
extracted from femurs and tibias and were placed in PBS, 0.1%
BSA (vol/vol). Equal numbers of bone marrow cells from congenic
WT (C57BL/6.SJL) (PtprcaPep3b; Ly5.1+) and homozygous feeble
mice (Ly5.2+) were injected intravenously into the lateral tail veins
of recipient feeble mice irradiated (1000 rad) 24 h earlier.
In vivo NK cell cytotoxicity assay
A total of 107 control C57BL/6J splenocytes or TAP1-deficient
splenocytes were resuspended in 1 mL PBS and labeled with low
(0.5 mM) and high (5 mM) concentrations of carboxyfluorescein
diacetate succinimidyl ester (CFSE) (Sigma-Aldrich), respectively,
at room temperature for 10 min. The labeling was stopped by
addition of cold FCS. Cells were washed twice, counted, and
resuspended at a concentration of 56107 cells/mL. The two
populations were mixed at a 1:1 ratio and injected i.v. into
recipient mice. Recipients were bled 24 hours later, and PBMCs
were analyzed for CFSE staining by flow cytometry.
Statistics
The statistical significance of differences was determined by
unpaired Student’s two-tailed t-test. Differences with a P value of
less than 0.05 were considered statistically significant. For all
figures: *P,0.05; **P#0.01; ***P#0.001. Unless marked, p.0.05
between WT and feeble and data groups were not statistically
Slc15a4 Is Required to Control a Persistent Virus
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significantly different. Error bars show standard error of the mean
(SEM).
Supporting Information
Figure S1 Slc15a4 is not required to control acute viral
infection. Serum and organs were collected at the indicated
times post LCMV Armstrong infection and infectious virus was
titered. WT and feeble mice infected i.v. with 26106 pfu of the
acute LCMV Armstrong strain. Animals were then sacrificed and
the indicated tissue was isolated for viral titers at 5 and 10 dpi.
Representative data of 2 independent experiments are shown;
n.= 3 per group. Unless marked, p.0.05 between WT and feeble
and not statistically significantly different.
(TIF)
Figure S2 Slc15a4 is not required for antigen specific T
cell responses against an acute LCMV Armstrong
infection in vivo. 8 days after LCMV Cl13 infection,
splenocytes from WT and feeble mice were cultured ex vivo with
the indicated peptides or without peptide for 5 hours and then
stained with antibodies to quantitate T cell antigen specific
production of IFN-c as well as double production of IFN-c, TNF-
a (CD8 T cells) and IFN- c, IL-2 (CD4 T cells), as labeled. Mean
and standard error of the mean are shown, N = 3. feeble,
Slc15a4feeble/feeble mice. Representative data of 2 independent
experiments are shown. There was no statistical difference
between WT and feeble.
(TIF)
Figure S3 feeble CD8 T cells and antigen presenting
cells do not display defects ex vivo. Spleens were harvested
from naı¨ve adult OT-I and OT-I; feeble mice. Whole splenocytes
were then cultured for 3 days with CFSE over a range of specific
peptide concentrations as indicated. Antigen induced cell
proliferation was enumerated by flow cytometry. One of 2
representative experiments is shown. feeble, Slc15a4feeble/feeble mice.
OT-I, ovalbumin-specific TCR transgenic line specific for the
CD8+ T cell immunodominant epitope SIINFEKL.
(TIF)
Figure S4 Intact intrinsic function of homozygous
Slc15a4feeble/feeble NK cells. Percentage of CFSE-labeled
Tap12/2 cells remaining in the blood of Tap12/2, C57BL/6J,
and feeble mice 24 h after injection of a 1:1 mixture of CFSE-
labeled Tap12/2 and WT splenocytes was measured by flow
cytometry. 1 of 2 independent experiments is shown with the same
results. There was no statistical difference between WT and feeble.
(TIF)
Figure S5 Immune cell recruitment and activation early
during splenic infection. Splenocytes were harvested from
WT and feeble mice 0, 1, 3 and 5 days post infection (A–D,
respectively) with LCMV Clone 13. Cells were counted and
stained with antibodies to surface markers to distinguish B cell, T
cell, dendritic cell (DC) and macrophage cell numbers. Cells were
also stained with antibodies to MHC Class I, Class II, CD80 and
CD86 to assess the activation status of B cells, macrophages and
DCs. Individual replicates, mean and standard error of the mean
(where indicated for total viable cells) are shown. n = 5 per group
of infected mice. 1 of 2 similar experiments is shown. Unless
marked, p.0.05 between WT and feeble and not statistically
significantly different.
(PDF)
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